XML 37 R25.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Equity - contributed equity | 12 Months Ended
--- | ---
Jun. 30, 2018
Text block1 [abstract] |
Equity - contributed equity | Note 21. Equity - contributed equity
|  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
|  | Shares |  |  | Shares |  |  | A$ |  |  | A$ |
Ordinary shares - fully paid |  |  | 48,409,621 |  |  |  | 483,287,914 |  |  |  | 31,575,824 |  |  |  | 193,769,409 |
Movements in ordinary share capital
Details |  | Date |  |  | Shares |  |  | Issue price |  |  | A$ |
Balance |  |  | July 1, 2016 |  |  |  | 429,733,982 |  |  |  |  |  |  |  | 191,301,217 |
Issue of shares - Note 2 |  |  | September 05, 2016 |  |  |  | 400,000 |  |  | $ | 0.105 |  |  |  | 42,000 |
Issue of shares - Convertible note conversion |  |  | September 14, 2016 |  |  |  | 20,000,000 |  |  | $ | 0.025 |  |  |  | 500,000 |
Issue of shares - Acquisition of Glioblast Pty Ltd |  |  | October 31, 2016 |  |  |  | 17,153,932 |  |  | $ | 0.090 |  |  |  | 1,543,854 |
Issue of shares - Convertible note conversion |  |  | November 01, 2016 |  |  |  | 16,000,000 |  |  | $ | 0.025 |  |  |  | 400,000 |
Share issue transaction costs |  |  |  |  |  |  | — |  |  | $ | 0.000 |  |  |  | (17,662 | )
Balance |  |  | June 30, 2017 |  |  |  | 483,287,914 |  |  |  |  |  |  |  | 193,769,409 |
Share consolidation - Note 1 |  |  | November 17, 2017 |  |  |  | (434,958,293 | ) |  | $ | 0.000 |  |  |  | — |
Issue of shares - Note 2 |  |  | November 30, 2017 |  |  |  | 80,000 |  |  | $ | 0.370 |  |  |  | 29,600 |
Cancellation of share capital - Note 3 |  |  | December 31, 2017 |  |  |  | — |  |  | $ | 0.000 |  |  |  | (162,223,185 | )
Balance |  |  | June 30, 2018 |  |  |  | 48,409,621 |  |  |  |  |  |  |  | 31,575,824 |
Ordinary shares Note 1 - Share consolidation 10 to 1, which was approved by shareholders at the Annual General Meeting on November 15, 2017 Note 2 - Shares issued to the Company’s Scientific Advisory Board in return for services Note 3 - Section 258F of the Corporations Act allows a company to reduce its share capital by cancelling any paid-up share capital that is lost or is not represented by available assets. Given the long history of the consolidated entity and changes in the principal activity in recent years, the Directors believe that A$162,223,185 of the parent entity’s share capital satisfies the criteria in Section 258F of the Corporations Act and accordingly this amount of the ordinary share capital has been cancelled. Ordinary shares Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital. On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. Share buy-back There is no current on-market share buy-back. Capital risk management The consolidated entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. The capital risk management policy remains unchanged from the prior year.

X
- Definition The disclosure of issued capital. [Refer: Issued capital] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2017-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_10_e&doctype=Standard -URIDate 2017-03-09 + Details
Name: | ifrs-full_DisclosureOfIssuedCapitalExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block. + References No definition available. + Details
Name: | kzia_TextBlock1Abstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration